Latest Insider Transactions at Recursion Pharmaceuticals, Inc. (RXRX)
This section provides a real-time view of insider transactions for Recursion Pharmaceuticals, Inc. (RXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RECURSION PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RECURSION PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 14
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
Apr 14
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,517
-4.48%
|
$241,619
$7.57 P/Share
|
|
Apr 14
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+4.57%
|
-
|
|
Apr 14
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,010
+10.28%
|
$88,020
$2.48 P/Share
|
|
Apr 08
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$15,000
$6.7 P/Share
|
|
Apr 08
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
Apr 08
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
36,920
-5.15%
|
$221,520
$6.59 P/Share
|
|
Apr 08
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+4.91%
|
-
|
|
Apr 08
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,010
+10.93%
|
$88,020
$2.48 P/Share
|
|
Apr 07
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$15,000
$6.51 P/Share
|
|
Apr 07
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
Apr 07
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
36,718
-5.51%
|
$220,308
$6.55 P/Share
|
|
Apr 07
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+5.26%
|
-
|
|
Apr 07
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,010
+11.68%
|
$88,020
$2.48 P/Share
|
|
Apr 06
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$15,000
$6.56 P/Share
|
|
Apr 06
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
Apr 06
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
35,826
-5.84%
|
$214,956
$6.78 P/Share
|
|
Apr 06
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+5.68%
|
-
|
|
Apr 06
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,010
+12.57%
|
$88,020
$2.48 P/Share
|
|
Apr 05
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$17,500
$7.32 P/Share
|
|
Apr 05
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
Apr 05
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,472
-6.17%
|
$241,304
$7.45 P/Share
|
|
Apr 05
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+6.19%
|
-
|
|
Apr 05
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,010
+13.67%
|
$88,020
$2.48 P/Share
|
|
Apr 01
2022
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,544
+0.26%
|
-
|
|
Apr 01
2022
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,438
+18.0%
|
-
|
|
Apr 01
2022
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,788
+1.29%
|
-
|
|
Apr 01
2022
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,300
+0.02%
|
-
|
|
Apr 01
2022
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,382
+33.43%
|
-
|
|
Mar 31
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,072
+6.92%
|
$18,144
$2.48 P/Share
|
|
Mar 15
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,150
-2.56%
|
$36,900
$6.08 P/Share
|
|
Mar 15
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
6,150
+2.5%
|
-
|
|
Mar 14
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
230,000
-49.57%
|
$1,380,000
$6.28 P/Share
|
|
Mar 14
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
230,000
+33.14%
|
-
|
|
Mar 11
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-29.94%
|
$600,000
$6.95 P/Share
|
|
Mar 11
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+23.04%
|
-
|
|
Mar 07
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
300,000
-56.18%
|
$2,100,000
$7.3 P/Share
|
|
Mar 07
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
300,000
+35.97%
|
-
|
|
Mar 04
2022
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
58,500
+21.95%
|
$58,500
$1.06 P/Share
|
|
Feb 28
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+12.16%
|
$31,250
$2.48 P/Share
|
|
Feb 22
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-29.94%
|
$1,000,000
$10.22 P/Share
|
|
Feb 22
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+23.04%
|
-
|
|
Feb 18
2022
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+9.67%
|
$16,000
$1.06 P/Share
|
|
Feb 14
2022
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+2.91%
|
$4,000
$1.06 P/Share
|
|
Feb 04
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
343
-0.15%
|
$3,773
$11.4 P/Share
|
|
Feb 04
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
210,893
+24.24%
|
-
|
|
Feb 04
2022
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
828
-0.64%
|
$9,108
$11.4 P/Share
|
|
Feb 04
2022
|
Tina Marriott Larson President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
82,005
+20.08%
|
-
|
|
Feb 04
2022
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
678
-0.11%
|
$7,458
$11.4 P/Share
|
|
Feb 04
2022
|
Michael Secora Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,299
+4.67%
|
-
|